Jobless Claims Come in Higher
Pre-market futures are in the green at this hour, at first appearing overjoyed at a federal court ruling that rolled back President Trump's tariff policy. Futures had been as high as +2.8% (Russell 2000; half that on the Dow: +1.4%), but have dragged closer to unchanged as the administration vows to appeal the court ruling, and perhaps find other ways to instill tariffs on U.S. trading partners.
Thus, the Dow is currently up +95 points, the S&P 500 +45 and the Nasdaq +285 points. The Russell is now +17, or +0.84%. Certainly better than a sharp stick in the eye, but now well off the bounce-back pace the indexes had been on earlier. Bond yields are holding fairly steady: +4.47% on the 10-year, +3.99% on the 2-year and +4.97% on the 30-year.
Initial Jobless Claims reached +240K last week, the highest single-week print we've seen in a month, and higher by 10K from consensus estimates. This bounds up from a downwardly revised 226K the prior week, and appears to indicate something of a softening in the labor market. Then again, these weekly numbers tend to get revised downward in future weeks. We can't say right now whether this is a new level or another multi-week blip on the screen.
Continuing Claims posted their highest single-week tally since November of 2021 at 1.919 million longer-term jobless claims. This is another metric we've seen revised below the psychological 1.9 million market routinely; indeed, this has happened on the previous week's revision, which moved from 1.903 million to 1.89 million this morning. Nevertheless, we're starting to see weekly claims warm up on the long-end, too.
The second print on Q1 2025 Gross Domestic Product (GDP) has hit the tape this morning, with a -0.2% headline improving 10 basis points (bps) from the first read, and 20 bps better than the -0.4% expected. Consumption dwindled from +1.8% to +1.2% on today's revision — the lightest we've seen since Q2 2023.
The big Personal Consumption Expenditures (PCE) report comes out tomorrow ahead of the opening bell, though today we get something of a sneak-peek: the Pricing Index reached +3.7%, in-line with expectations and -10 bps from the first read. The Core Pricing Index came in at +3.4%, which is the highest level we've seen since Q1 2024. It's also the third-straight higher quarter.
Best Buy BBY posted decent numbers in its Q1 report ahead of today's open: earnings of $1.15 per share came ahead of the $1.09 expected, while revenues were a smidge better than anticipated to $8.77 billion.
The big-box retailer's comps were lower, but better than expected. However, tariff conditions have led the company to cut guidance, leading to a -3% sell-off in today's pre-market. Shares had already been down -16% year to date.
Kohl's KSS posted a surprisingly good Q1 this morning, with its loss of -$0.13 per share much improved from the -$0.22 analysts had been expecting. Revenues of $3.23 billion outpaced estimates by +0.88%. Importantly, the company kept its forward guidance intact; shares are up +7% in today's pre-market (though still have a ways to go to get to break-even on the year).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Kohl's Corporation (KSS) : Free Stock Analysis Report
Best Buy Co., Inc. (BBY) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Why Blueprint Medicines Corporation (BPMC) Skyrocketed On Monday
We recently published a list of . In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other top-performing stocks on Monday. Blueprint Medicines soared by 26.09 percent on Monday to close at $127.79 each following news that it is set to be acquired by French pharmaceutical giant Sanofi for $9.1 billion. Under the agreement, Sanofi will commence a tender offer to acquire shares of Blueprint Medicines Corporation (NASDAQ:BPMC) at a price of $129 apiece for a total equity value of $9.1 billion. A doctor examining a patient's samples in a modern hospital setting. In addition, shareholders will be able to receive one non-tradable contingent value right (CVR), which will entitle them to two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. The upfront offer price represents a 27-percent premium over Blueprint's closing price on May 30, 2025, and a premium of approximately 34 percent over the 30 trading days of its volume-weighted average price (VWAP) as of May 30, 2025. The purchase will also include the latter's rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM). READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

Yahoo
27 minutes ago
- Yahoo
Education Department pausing plan to garnish Social Security checks over defaulted loans
The Department of Education has not gone through with a plan to garnish Social Security checks over defaulted loans, a department spokesperson told The Hill. 'The Department has not offset any social security benefits since restarting collections on May 5, and has put a pause on any future social security offsets,' Ellen Keast, the spokesperson, said. The department announced in April that student loan borrowers in default, or people who have not paid their loans for more than 270 days, had the chance of seeing financial consequences including stopped federal payments like Social Security and garnished wages. The changes could have impacted the lives of over 5 million borrowers. 'The Trump Administration is committed to protecting social security recipients who oftentimes rely on a fixed income,' Keast said. 'In the coming weeks, the Department will begin proactive outreach to recipients about affordable loan repayment options and help them back into good standing.' In March, President Trump said that he was 'immediately' moving the handling of federal student loans from the Department of Education to the Small Business Administration (SBA). 'I've decided that the SBA, the Small Business Administration, headed by Kelly Loeffler … will handle all of the student loan portfolio,' Trump said to reporters in the Oval Office at the time, saying it was a 'pretty complicated deal, and that's coming out of the Department of Education immediately.' 'And also, Bobby Kennedy, with the Health and Human Services Department, will be handling special needs and all the nutrition programs and everything else,' he continued. 'I think that will work out very well. Those two elements will be taken out of the Department of Education.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.


Business Insider
39 minutes ago
- Business Insider
AppLovin (APP): New Buy Recommendation for This Technology Giant
In a report released today, James Heaney CFA from Jefferies reiterated a Buy rating on AppLovin (APP – Research Report), with a price target of $530.00. Confident Investing Starts Here: Heaney CFA covers the Communication Services sector, focusing on stocks such as Netflix, Walt Disney, and Snap. According to TipRanks, Heaney CFA has an average return of 21.5% and a 43.62% success rate on recommended stocks. In addition to Jefferies, AppLovin also received a Buy from BTIG's Clark Lampen in a report issued on May 30. However, on May 28, Needham maintained a Hold rating on AppLovin (NASDAQ: APP). The company has a one-year high of $525.15 and a one-year low of $60.67. Currently, AppLovin has an average volume of 8.85M. Based on the recent corporate insider activity of 106 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of APP in relation to earlier this year. Last month, Arash Adam Foroughi, the CEO & Chairperson of APP sold 133,700.00 shares for a total of $49,070,352.34.